|
GRIP1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.63891122895166E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.55031584528842E-15 |
| Normal-vs-Stage2 |
6.86839999985978E-07 |
| Normal-vs-Stage3 |
4.93139995505487E-09 |
| Normal-vs-Stage4 |
1.62481139653892E-12 |
| Stage1-vs-Stage2 |
1.848410E-01 |
| Stage1-vs-Stage3 |
6.081000E-01 |
| Stage1-vs-Stage4 |
3.758600E-03 |
| Stage2-vs-Stage3 |
4.942400E-01 |
| Stage2-vs-Stage4 |
3.597400E-03 |
| Stage3-vs-Stage4 |
2.097600E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.43249864695372E-13 |
| Normal-vs-AfricanAmerican |
6.55059999576935E-08 |
| Normal-vs-Asian |
3.8266000368381E-09 |
| Caucasian-vs-AfricanAmerican |
3.911800E-01 |
| Caucasian-vs-Asian |
5.170200E-01 |
| AfricanAmerican-vs-Asian |
7.538200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.98139332403025E-13 |
| Normal-vs-Female |
1.86006765545699E-12 |
| Male-vs-Female |
8.394800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.77202696960421E-12 |
| Normal-vs-Age(41-60Yrs) |
4.69070338127153E-11 |
| Normal-vs-Age(61-80Yrs) |
3.82620046757154E-10 |
| Normal-vs-Age(81-100Yrs) |
1.616400E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.327400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.218400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.482400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.748200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.625200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.702000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.616200E-01 |
| Classical-VS-Follicular |
7.485000E-01 |
| Classical-VS-Other |
3.707000E-01 |
| Classical-VS-Normal |
1.72595271408227E-12 |
| Tall-VS-Follicular |
3.435200E-01 |
| Tall-VS-Other |
3.476200E-01 |
| Tall-VS-Normal |
1.19359966355148E-10 |
| Follicular-VS-Other |
5.016800E-01 |
| Follicular-VS-Normal |
1.26820000057037E-08 |
| Other-VS-Normal |
3.389600E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.38538094726937E-14 |
| Normal-vs-N1 |
2.88179999974325E-07 |
| N0-vs-N1 |
8.322000E-01 |
|
|
